Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients
Authors:
- 22 December 2016
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 64 (5) , 605-613
Abstract
Background.: Vancomycin-resistant Enterococcus bloodstream infections (VRE-BSIs) are associated with significant mortality. Daptomycin exhibits concentration-dependent activity vs VRE in vitro, yet the clinical impact of higher-dose strategies remains unclear. Methods.: We performed a national retrospective cohort study of hospitalized Veterans Affairs patients treated with standard-dose (6 mg/kg total body weight), medium-dose (8 mg/kg total body weight), or high-dose (≥10 mg/kg total body weight) daptomycin for VRE-BSI. Patient-related, microbiological, and outcomes data were abstracted from clinical databases. The primary outcome was overall survival, evaluated by Cox regression. Secondary outcomes included 30-day mortality, time to microbiological clearance, and creatine phosphokinase (CPK) elevation. Results.: A total of 911 patients were included (standard dose, n = 709; medium dose, n = 142; high dose, n = 60). Compared to high-dose daptomycin, both standard-dose (hazard ratio [HR], 2.68; 95% confidence interval; [CI], 1.33–3.06; P = .002) and medium-dose (HR, 2.66; 95% CI, 1.33–3.92; P = .003) daptomycin were associated with poorer survival. After adjusting for confounders, the relationship between poorer survival and standard-dose (adjusted HR [aHR], 2.58; 95% CI, 1.27–4.88; P = .004) and medium-dose (aHR, 2.52; 95% CI, 1.27–5.00; P = .008) daptomycin persisted. Thirty-day mortality was significantly lower among high-dose daptomycin–treated patients compared with other dosing strategies (risk ratio, 0.83; 95% CI, .74–.94; P = .015). Compared with standard-dose daptomycin, both medium-dose (HR, 0.78; 95% CI, .55–.90; P = .012) and high-dose daptomycin (HR, 0.70; 95% CI, .41–.84; P = .006) were associated with significantly improved microbiological clearance. No difference in the risk of CPK elevation was observed between the treatment groups (P = .504). Conclusions.: High-dose daptomycin was associated with improved survival and microbiological clearance in VRE-BSI.Keywords
This publication has 42 references indexed in Scilit:
- Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin doseClinical Microbiology and Infection, 2016
- Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysisInternational Journal of Antimicrobial Agents, 2016
- Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin® Outcomes Registry and ExperienceAdvances in Therapy, 2015
- Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: Summary of 8 years of a Worldwide Surveillance Programme (2005–2012)International Journal of Antimicrobial Agents, 2014
- High-dose daptomycin in documented Staphylococcus aureus infectionsInternational Journal of Antimicrobial Agents, 2010
- The Value of Infectious Diseases Consultation in Staphylococcus aureus BacteremiaThe American Journal of Medicine, 2010
- The burden of vancomycin-resistant enterococcal infections in US hospitals, 2003 to 2004Diagnostic Microbiology and Infectious Disease, 2008
- Drug-Induced Immune ThrombocytopeniaNew England Journal of Medicine, 2007
- Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance programDiagnostic Microbiology and Infectious Disease, 2007
- A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia☆Diagnostic Microbiology and Infectious Disease, 2000